Our Pricing

Access Mounjaro Now: UK Weight Loss Injections Available

Searching for mounjaro weight loss injections uk online with transparent pricing and expert clinical support? Cured Pharmacy offers genuine UK-licensed Mounjaro (tirzepatide) from £135.00 with free online consultations completed in under three minutes by our UK-registered prescribers. All treatments are dispensed discreetly with next-day delivery available across the UK.

How Mounjaro Weight Loss Injections Work in the UK

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike earlier single-pathway treatments, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, creating a synergistic effect that regulates appetite, slows gastric emptying, and improves insulin sensitivity.

In the landmark SURPASS-3 clinical trial, participants receiving the 15mg maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks—significantly greater than comparator treatments [1]. The dual-receptor mechanism appears to produce superior metabolic benefits compared to GLP-1-only medications, though individual responses vary based on baseline weight, adherence, and lifestyle factors.

Mounjaro is administered as a once-weekly subcutaneous injection using the KwikPen device. Dosing begins at 2.5mg weekly for four weeks, then escalates gradually to minimise gastrointestinal side effects. Your UK prescriber will determine your optimal maintenance dose (ranging from 5mg to 15mg) based on tolerability and clinical response during follow-up assessments [2].

Mounjaro vs Wegovy: Comparing UK Weight Loss Injections

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are injectable medications licensed in the UK for chronic weight management, but they differ in their pharmacological mechanisms and clinical outcomes. Wegovy activates GLP-1 receptors exclusively, whilst Mounjaro targets both GIP and GLP-1 pathways, which may explain the greater average weight reduction observed in head-to-head comparisons [3].

In the SURPASS-2 trial, tirzepatide demonstrated superior weight loss compared to semaglutide 1mg, with the highest tirzepatide dose producing approximately 5-7% greater body weight reduction at 40 weeks [3]. However, Wegovy remains an excellent option for many patients, particularly those who respond well to GLP-1-only therapy or prefer a treatment with a longer UK prescribing history.

Both medications require once-weekly injections and share similar side effect profiles, predominantly gastrointestinal symptoms during dose escalation. Your prescriber will consider your medical history, previous treatment responses, and individual risk factors when recommending the most appropriate option during your clinical assessment.

Which Treatment Is Right for You?

Choosing between Mounjaro and Wegovy depends on multiple factors including your BMI, previous medication trials, comorbidities such as type 2 diabetes, and cost considerations. Patients with a history of inadequate response to GLP-1-only therapies may benefit from Mounjaro's dual-receptor action, whilst those seeking the most cost-effective option might prefer Wegovy's lower starting price point. Our UK prescribers evaluate your complete clinical picture during the free online consultation to recommend the treatment most likely to support your weight management goals safely and effectively.

Clinical Evidence: What UK Trials Show About Mounjaro

The SURPASS clinical trial programme represents the most comprehensive evaluation of tirzepatide for weight management, enrolling over 6,500 participants across multiple international sites including UK centres [1]. SURPASS-1 through SURPASS-5 examined different patient populations, comparators, and treatment durations, consistently demonstrating dose-dependent weight reduction and metabolic improvements.

In SURPASS-3, which compared tirzepatide against insulin degludec in people with type 2 diabetes, participants on the 15mg dose lost an average of 13.9kg compared to 2.3kg weight gain in the insulin group over 52 weeks [4]. Importantly, these results were achieved alongside significant HbA1c reductions, demonstrating dual metabolic benefits. Similar weight loss outcomes were observed in participants without diabetes in the SURMOUNT-1 trial, where average reductions reached 22.5% of baseline body weight at 72 weeks [1].

Long-term safety data from these trials showed that the most common adverse events were gastrointestinal—primarily nausea, diarrhoea, and constipation—which typically diminished after the initial dose-escalation period. Serious adverse events occurred at similar rates to comparator groups, and discontinuation rates due to side effects remained below 15% across most trials [2][4].

Real-World Outcomes in UK Clinical Practice

Since Mounjaro's UK launch in 2023, real-world prescribing data suggests clinical outcomes align closely with trial results when patients adhere to treatment protocols and maintain supportive lifestyle modifications. Our clinical team at Cured Pharmacy monitors patient progress through regular follow-up consultations, adjusting doses as needed and providing guidance on managing transient side effects. Whilst individual results vary, patients who complete the full dose-escalation schedule and remain on treatment for at least six months typically achieve clinically meaningful weight reduction of 10% or greater from baseline.

How to Access Mounjaro Weight Loss Injections UK Online

Mounjaro is a prescription-only medication in the UK, meaning you cannot purchase it without a clinical assessment by a UK-registered prescriber. At Cured Pharmacy, the process begins with a free online consultation that takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight management goals, and any contraindications such as personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Our clinical team—overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073)—reviews your assessment within hours. If Mounjaro is deemed clinically appropriate and safe for you, a UK prescriber will issue a private prescription and your medication will be dispensed from our GPhC-registered pharmacy (9012511). All Mounjaro supplied through Cured Pharmacy is genuine UK-licensed stock sourced directly from licensed wholesalers, never grey-market imports.

Once approved, your Mounjaro KwikPen is dispatched in 100% discreet packaging with next-day delivery available across England, Scotland, Wales, and Northern Ireland. Each pen comes with full patient information leaflets, and our pharmacy team remains available via phone (+44 116 4646009) for any questions about injection technique, storage, or side effect management throughout your treatment journey.

Mounjaro Pricing: Transparent Costs at UK Pharmacies

At Cured Pharmacy, Mounjaro weight loss injections start from £135.00 per pen, with transparent pricing displayed before you begin your clinical consultation. Unlike some providers who reveal costs only after lengthy assessments, we believe patients deserve upfront clarity about treatment expenses. Final pricing depends on your prescribed dose—lower maintenance doses cost less per month than higher-strength options.

We guarantee the lowest prices in the UK for genuine, licensed Mounjaro. If you find a lower price at another UK-registered pharmacy for the same product and dose, we'll match it. There are no hidden fees: the price you see includes the medication, clinical consultation, and standard delivery. Expedited next-day delivery incurs a small additional charge, clearly itemised at checkout.

Many patients ask whether Mounjaro is available on the NHS. Currently, NHS England has restricted Mounjaro prescribing to specialist weight management services due to capacity constraints, making private prescription the most accessible route for most UK patients. Private treatment allows faster access without lengthy waiting lists, and you retain full control over your treatment timeline and follow-up schedule.

Comparing Costs Across Weight Loss Treatments

Whilst Mounjaro represents a premium option due to its superior clinical outcomes, other effective weight loss treatments are available at lower price points. Wegovy starts from £135.00 and delivers excellent results for many patients, particularly those who respond well to GLP-1-only therapy. Saxenda, a daily injection, begins from £135.00 and may suit those preferring more frequent, lower-dose administration. Oral medications like Orlistat offer the most budget-friendly option from £135.00, though with more modest average weight loss compared to injectable GLP-1 treatments. Our prescribers help you balance clinical effectiveness, tolerability, and cost to identify the optimal treatment within your budget.

Managing Side Effects and Maximising Results with Mounjaro

The most frequently reported side effects of Mounjaro are gastrointestinal: nausea affects approximately 20-30% of patients during initial dose escalation, whilst diarrhoea, constipation, and reduced appetite occur in 15-25% [2]. These symptoms typically peak during the first few weeks after each dose increase, then diminish as your body adapts. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce nausea severity.

Serious adverse events are rare but include potential risks of pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concurrent diabetes medications). Mounjaro carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans. It remains contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome [5].

To maximise weight loss outcomes, Mounjaro should be combined with a reduced-calorie diet and increased physical activity. Clinical trials demonstrating 20%+ weight reduction included structured lifestyle interventions alongside medication [1]. Our clinical team provides guidance on sustainable dietary changes and exercise programmes during follow-up consultations. Patients who view Mounjaro as one component of comprehensive weight management—rather than a standalone solution—achieve the most significant and durable results.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain (which may indicate pancreatitis), persistent vomiting leading to dehydration, or signs of allergic reaction such as rash, swelling, or difficulty breathing. Contact your prescriber if gastrointestinal side effects persist beyond four weeks, if you experience unexplained weight gain despite adherence, or if you develop symptoms of gallbladder disease such as jaundice or right upper quadrant pain. Regular follow-up assessments—typically at 4, 12, and 24 weeks—allow your clinical team to monitor progress, adjust dosing, and address any emerging concerns promptly.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet, 398(10295), 143–155. https://doi.org/10.1016/S0140-6736(21)01324-6
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4
5. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/14881

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.